NCT03199807 (LCRAI-1) is a Phase 1, PHASE2 clinical trial of NRT in HCC, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

What drugs are being tested in NCT03199807?

Interventions in NCT03199807: NRT, Radiotherapy.

Is NCT03199807 still recruiting?

NCT03199807 is currently status unknown. Last updated 27 June 2017.

Last reviewed 2017-06-27 · How we verify

NCT03199807: LCRAI-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IB/II Study of NRT Combined With Radiotherapy for Advanced HCC

Status unknown Phase 1, PHASE2 Last updated 27 June 2017

What this trial tests

Phase 1, PHASE2 trial testing NRT in HCC in 40 participants. Status unknown.

Timeline

20 July 2017

Primary endpoint
20 July 2020

20 July 2021

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	20 July 2017
Primary completion	20 July 2020
Estimated completion	20 July 2021

Drugs / interventions tested

NRT
Radiotherapy — full drug profile →

Conditions studied

HCC — all drugs for HCC →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 18 to 75, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study herein successfully developed a new immunotherapeutic approach combined with radiotherapy, and tried to proved it to be more effective and safe.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Khanam A, Kottilil S. · · 2022 · cited 17× · PMID 36613878 · DOI 10.3390/ijms24010437
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.
Chen P, Fang QX, Chen DB, Chen HS. · · 2021 · cited 12× · PMID 34322196 · DOI 10.4251/wjgo.v13.i7.673
Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report.
Liu C, Shao J, Dong Y, Xu Q, et al · · 2021 · cited 9× · PMID 34326839 · DOI 10.3389/fimmu.2021.685126
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches.
Huang R, Zhao B, Hu S, Zhang Q, et al · · 2023 · cited 8× · PMID 37062844 · DOI 10.1186/s40364-023-00478-5
Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment.
Aggeletopoulou I, Pantzios S, Triantos C. · · 2025 · cited 6× · PMID 39941745 · DOI 10.3390/cancers17030376
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.
Naffaa MM, Al-Ewaidat OA, Gogia S, Begiashvili V. · · 2025 · cited 4× · PMID 40309350 · DOI 10.37349/etat.2025.1002313
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment.
Han R, Wang Y, Lu L. · · 2023 · cited 4× · PMID 38258070 · DOI 10.3390/pharmaceutics16010059

Verify or expand the search:

Other recruiting trials for HCC

Currently open trials in the same condition.

NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03199807 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 27 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03199807.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing